Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Sangamo Therapeutics (NASDAQ:SGMO) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.70 million.

Sangamo Therapeutics Trading Down 16.2 %

Shares of NASDAQ:SGMO opened at $0.85 on Wednesday. The company has a market capitalization of $176.54 million, a PE ratio of -1.13 and a beta of 1.49. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.41.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SGMO shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday. Jefferies Financial Group decreased their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Wells Fargo & Company reduced their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Finally, Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.